COMMUNIQUÉS West-GlobeNewswire

AB Science annonce l’initiation de la couverture de son titre par deux sociétés d’analyse financières, DNA Finance d’une part, et par In Extenso Finance d’autre part
06/03/2024
COMMUNIQUE DE PRESSE DEUX NOUVELLES SOCIETES D’ANALYSE FINANCIERE INITIENT LA COUVERTURE DU TITRE AB SCIENCE Paris, 6 mars 2024, 20h15 AB Science SA (Euronext - FR0010557264 - AB) annonce l’initiation de la couverture [...]
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
06/03/2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into [...]
ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication
06/03/2024
LOS ANGELES, March 06, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented the oral abstract “Long-Acting Injectable CAB/RPV is Superior to Oral [...]
NMDP Awards 25th Annual ‘Amy Scholars’ Grant, Furthering Post-Transplant Research
06/03/2024
NMDP also recognizes its first Barbara Buchbinder Nurse Research Grant recipient, helping improve patient experience and outcomes MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- NMDP℠ announced two recipients of its Amy [...]
Robot-Assisted Dental Implant Placement Most Accurate and Precise Treatment Modality According to Landmark Study by Leading Oral Surgeon
06/03/2024
Dr. Jay Neugarten, an international thought leader in implant dentistry and early adopter of dental robotics, publishes clinical study on the unparalleled accuracy and precision of dental implantation assisted by the [...]
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
06/03/2024
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
06/03/2024
Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask. Featuring the AdaptiSeal ™ [...]
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
06/03/2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe [...]
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
06/03/2024
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), (the “Company”), a clinical stage biotechnology [...]
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
06/03/2024
Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology [...]
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
06/03/2024
-- Paving the way forward for the broader commercial availability of FemaSeed, an accessible, safe, and cost effective alternative to IVF -- -- Ongoing uncertainty following recent Alabama Supreme Court Ruling creates [...]
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
06/03/2024
Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk of progression or death, compared to standard of care regimen 1 [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
06/03/2024
Please see enclosed pdf. Attachment 06032024_trading_in_shares_ASL
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
06/03/2024
Please see enclosed pdf. Attachment 06032024_trading_in_shares_KVI
SFWJ DBA MedCana Completes Acquisition of Two Additional Cannabis Companies, Solidifying Market Leadership
06/03/2024
AUSTIN, Texas, March 06, 2024 (GLOBE NEWSWIRE) -- Following its recent announcement, SFWJ DBA MedCana , a premier holding company in the cannabis industry, is delighted to confirm the successful acquisition of two [...]
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
06/03/2024
Clinical study evaluated impact of AVIM therapy as compared to standard pacing using invasive pressure-volume loop analysis in 16 hypertensive pacemaker-indicated patients Results demonstrate statistically significant [...]
CorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
06/03/2024
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of [...]
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
06/03/2024
Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placebo Data published in Journal of Psychiatric Research [...]
Sofwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
06/03/2024
– Full fiscal 2023 revenue of $50.3M, +41% year-over-year growth; gross margin of 74. 5 % – F ull fiscal 2023 pulse recurring revenue of $ 13 .0 M, + 81 % year-over-year growth – Fourth quarter revenue of $15.3M, +11% [...]

Pages